Mydriasis Market, Size, Share, Trends, Epidemiology Forecast till 2030
Mydriasis is the dilation of the pupil, which may be due to a non-physiological cause such as disease, trauma, drugs usage, or physiological pupillary response.
Currently, dilation is achieved by topical and/or intracameral administration of anticholinergic agents, sympathomimetic agents, or both, with the most commonly used being cyclopentolate, tropicamide, and phenylephrine. Topical mydriatic agents have been used for many years to dilate the pupil before cataract surgery. Moreover, ophthalmologists have been in search of new options to streamline the process of intraoperative mydriasis.
The approved therapies are the only current treatment available in the market of mydriasis, and there is a dearth of novel products in the pipeline. Furthermore, Omidria is going to generate the highest revenue, followed by topical regimen and intracameral Injections. Along with these approved therapies, the approval of Nyxol, a topical eye drop for the treatment of reversal of mydriasis in the future, can also contribute to the market in the forecast period.
Mydriasis Market Insight
Mydriasis market size in 7MM in 2017 was USD 104.52 million
- Rising Geriatric population
- Cost-effectiveness of the Current Standard of Care
- Availability of Generic Options
- Limited Research & Development
Scope of the Report
- The report covers the descriptive overview of Mydriasis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Mydriasis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Mydriasis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Mydriasis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Mydriasis market
1. Key Insights
2. Executive Summary of Mydriasis
3. Competitive Intelligence Analysis for Mydriasis
4. Mydriasis: Market Overview at a Glance
4.1. Mydriasis Total Market Share (%) Distribution in 2017
4.2. Mydriasis Total Market Share (%) Distribution in 2030
5. Mydriasis: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Mydriasis Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Mydriasis Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Mydriasis Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Mydriasis Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Mydriasis Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Mydriasis Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Mydriasis Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Mydriasis Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Mydriasis Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Mydriasis Treatment and Management
8.2. Mydriasis Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Mydriasis Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Mydriasis: Seven Major Market Analysis
13.1. Key Findings
13.2. Mydriasis Market Size in 7MM
13.3. Mydriasis Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Mydriasis Total Market Size in the United States
15.1.2. Mydriasis Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Mydriasis Total Market Size in Germany
15.3.2. Mydriasis Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Mydriasis Total Market Size in France
15.4.2. Mydriasis Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Mydriasis Total Market Size in Italy
15.5.2. Mydriasis Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Mydriasis Total Market Size in Spain
15.6.2. Mydriasis Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Mydriasis Total Market Size in the United Kingdom
15.7.2. Mydriasis Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Mydriasis Total Market Size in Japan
15.8.3. Mydriasis Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Mydriasis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/